Systemic Sclerosis-Associated Interstitial Lung Disease
Publication Date: September 28, 2023
Key Points
Key Points
- Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc).
- The standard of care for patients with SSc includes lifestyle modification measures to minimize risks for overt and/or occult micro-aspiration, with or without treatment with proton pump inhibitors (PPI), H2-blockers, and/or prokinetic agents.
- Associated manifestations of SSc not addressed in this guideline include pulmonary hypertension, esophageal dysmotility, and gastroesophageal reflux disease (GERD).
- ILD is defined as the radiologic presence of reticulation, traction bronchiectasis, traction bronchiolectasis, honeycomb cysts, ground glass opacities/air space consolidation, other interstitial lung abnormalities, or any of the recognized patterns of interstitial pneumonias (usual interstitial pneumonia (UIP), probable UIP, indeterminate for UIP; non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP), lymphoid interstitial pneumonia (LIP), pleuroparenchymal fibroelastosis (PPFE), or unclassifiable interstitial pneumonias) reported in the context of SSc.
Treatment
...atment...
The recommendation for the use of th...
...mide (Low, Conditional Recommendation)3094...
...uximab (Very low, Conditional Recommendation)30...
...ab (Very low, Conditional Recommendation)3094444...
...ib (Very low, Conditional Recommend...
...naib plus mycophenolate (Very low,...
...ery low, Strong Recommendation)3094444...
...lus mycophenolate (Very low, Strong Re...
...e taken in using systemic corticoste...
...ry of Treatment Recommendations for Pa...